Share this

• UK Biotech company
• Supported by 3 FTEs for 6 months
• 300 g of API provided
• Route developed to avoid an unstable intermediate and remove all chromatography
• Overall yield of route increased from 3% to 16%
• New key starting material identified, 9-times cheaper than original starting material
• Technology transfer package and follow-on support provided to cGMP manufacturer

Our Chemical Development team has extensive knowledge and experience of the challenges facing the transition from typical synthetic routes used in medicinal chemistry to developing a robust and scalable process to enable delivery of multi-kg batches.

Related Case Studies

Medicinal Chemistry

Medicinal Chemistry Hit-to-Lead (H2L) 2

view case study
Medicinal Chemistry

Medicinal Chemistry: Hit-to-Lead (H2L)

view case study